Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
BACKGROUND: The literature provides data on the mechanisms of increasing levels of high-sensitivity cardiac troponin (hs-cTn) in the absence of cardiomyocyte death, including in hypertension, and the causes are currently not thoroughly examined. AIM: This study aimed to establish the factors associated with changes in hs-cTn level in patients with the initial stages of hypertension. MATERIALS AND METHODS: The study included 43 patients with arterial hypertension from February 1 to April 1, 2023. All the included patients underwent a standard clinical and instrumental examination, and the concentrations of hs-cTn I and the N-terminal fragment of the precursor of the cerebral natriuretic peptide were determined. A predictive model of the probability of determining the hs-sTp I level above the reference values was constructed using the logistic regression method. The differences were considered significant at p 0.05. RESULTS: The hs-sTp I level was 0.1 ng/mL in 29 patients, and the median, minimum, and maximum levels in all patients were 0.17 [0.10; 0.22], 0.07 , and 0.36 ng/mL, respectively. The predictor of changes in hs-sTp I level above the reference values was creatinine, with an odds ratio of 1.071 (95% confidence interval (CI) 1.003–1.145, p=0.041), and the predictor of finding the hs-sTp I level within the reference was the number of antihypertensive drugs taken: an increase in the “number of antihypertensive drugs” when determining the concentration of hs-sTp I above the norm decreased by 3.336 times (95% CI 0.105–0.854, p=0.024). CONCLUSION: This pilot prospective study of patients with stage 1 and 2 hypertension demonstrated an association between an increase in serum creatinine and an increase in hs-sTp I levels and between the number of antihypertensive medications taken by the patient and a decrease in hs-sTp I levels. The results must be confirmed by a longitudinal prospective study of a large sample of patients, and the relationship of the data obtained with short- and long-term prognosis in people with hypertension must be determined.
BACKGROUND: The literature provides data on the mechanisms of increasing levels of high-sensitivity cardiac troponin (hs-cTn) in the absence of cardiomyocyte death, including in hypertension, and the causes are currently not thoroughly examined. AIM: This study aimed to establish the factors associated with changes in hs-cTn level in patients with the initial stages of hypertension. MATERIALS AND METHODS: The study included 43 patients with arterial hypertension from February 1 to April 1, 2023. All the included patients underwent a standard clinical and instrumental examination, and the concentrations of hs-cTn I and the N-terminal fragment of the precursor of the cerebral natriuretic peptide were determined. A predictive model of the probability of determining the hs-sTp I level above the reference values was constructed using the logistic regression method. The differences were considered significant at p 0.05. RESULTS: The hs-sTp I level was 0.1 ng/mL in 29 patients, and the median, minimum, and maximum levels in all patients were 0.17 [0.10; 0.22], 0.07 , and 0.36 ng/mL, respectively. The predictor of changes in hs-sTp I level above the reference values was creatinine, with an odds ratio of 1.071 (95% confidence interval (CI) 1.003–1.145, p=0.041), and the predictor of finding the hs-sTp I level within the reference was the number of antihypertensive drugs taken: an increase in the “number of antihypertensive drugs” when determining the concentration of hs-sTp I above the norm decreased by 3.336 times (95% CI 0.105–0.854, p=0.024). CONCLUSION: This pilot prospective study of patients with stage 1 and 2 hypertension demonstrated an association between an increase in serum creatinine and an increase in hs-sTp I levels and between the number of antihypertensive medications taken by the patient and a decrease in hs-sTp I levels. The results must be confirmed by a longitudinal prospective study of a large sample of patients, and the relationship of the data obtained with short- and long-term prognosis in people with hypertension must be determined.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.